Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F. Ambinder

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamideLeo Luznik, Paul V O'Donnell, Heather J Symons, et al.
Science Translational Medicine|May 15, 2020
Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic targetRunxia Liu, Yang-Hui Jimmy Yeh, Ales Varabyou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 17, 2018
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related DonorsHany Elmariah, Yvette L Kasamon, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyErin Reid, Gita Suneja, Richard F Ambinder, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyErin Reid, Gita Suneja, Richard F Ambinder, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamideLeo Luznik, Paul V O'Donnell, Heather J Symons, et al.
Science Translational Medicine|May 15, 2020
Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic targetRunxia Liu, Yang-Hui Jimmy Yeh, Ales Varabyou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 17, 2018
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related DonorsHany Elmariah, Yvette L Kasamon, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyErin Reid, Gita Suneja, Richard F Ambinder, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyErin Reid, Gita Suneja, Richard F Ambinder, et al.
Pageof 22